Kamada Ltd. (TASE: KMDA) today notified the Tel Aviv Stock Exchange (TASE) that it has submitted a Biological License Application (BLA) with the US Food and Drug Administration (FDA) for the company's Alpha-1 Antitrypsin (AAT) protein for the treatment of congenital emphysema.
The company filed the application following success in the Phase III clinical trial for AAT in the US. The company received notice of the success in April 2008.